Isopropyl myristate

Sucrose erucic acid ester (Mitsubishi
Chemical Foods Co., Tokyo,
Japan) was added to isopropyl myristate (Fujifilm Wako Pure Chemical
Co., Osaka, Japan) and dissolved by shaking at room temperature to
form the oil phase.
The ethyl(dimethylaminopropyl)carbodiimide/N-hydroxysuccinimide (EDC/NHS) solution was prepared by
adding 10 mg/mL EDC (Peptide Institute Inc., Osaka, Japan) and 6 mg/mL
NHS (WAKO) into a 0.05 M 2-morpholinoethanesulfonic acid monohydrate
buffer (pH 5.6; Dojindo Laboratory, Kumamoto, Japan) solution. The
EDC/NHS solution and heparin (10 mg/mL; WAKO) were then added to a
5% gelatin (porcine-skin-derived gelatin type A; Sigma Aldrich, St.
Louis, MO) solution to form the aqueous phase. Next, the aqueous phase
was mixed with the oil phase via agitation using an ultrasonic homogenizer
(Sonifier 250; Branson Ultrasonic Co, Danbury, CT) at 1 pulse per
0.7 s, high-speed stirring, and 70% power amplitude resulting in a
milky-form liquid. The prepared emulsion was cooled at 4 °C to
jellify the aqueous phase into particles to obtain the G/O-NGD. The
prepared G/O-NGD was monodispersed in nature (PdI < 0.3) with a
mean particle diameter of <250 nm, as obtained in the previous
study.^{23 (link)}